tbuckley/cabot-search huggingface dataset:
Performance of community-based lung cancer screening program in a region with a high rate of endemic histoplasmosis.
Authors: Shruti Bhandari, Prashant Gyanendra Tripathi, Christina M Pinkston, Goetz H. Kloecker
Journal: Journal of Clinical Oncology (2018)

58 Background: Lung cancer screening (LCS) with Low dose computed-tomography (LDCT) has been recommended by USPSTF for high-risk population since 2013 largely based on 20% relative reduction in lung cancer mortality shown in National Lung Screening Trial (NLST). The success of NLST was related to its high adherence rate and thorough ascertainment of lung cancers and deaths. This study evaluated performance of lung cancer screening program in Histoplasmosis endemic community. Methods: Demographic and clinical information was collected through retrospective review on all patients in the lung cancer screening program of a Kentucky health system comprising 21 centers from 2016 and 2017. A positive LDCT screen is defined as Lung-RADS version 1.0 assessment categories 3 or 4. Results: A total of 4500 LDCT screens were performed in 2016 (39%) and 2017 (61%) with 49% adherence rate to repeat annual screen in 2017. Mean age of patients was 64 years, majority being females (54%) and current smokers (69%) with average 52-pack year smoking history. The rate of positive LDCT was 13.3% (600) varying based on initial (14.6%) vs annual (9.5%) screen. A total of 70 lung cancers were diagnosed among all positive LDCT screens (11.7%) with a false positive rate of 12%. Conclusions: Comparing to NLST results updated with Lung-RADS categories, baseline positive screens in our community are similar (14.6% vs 13.6%, p = 0.15) despite being a Histoplasmosis endemic region. Our higher rate of annual positive screens (9.5% vs 6%, p &lt; 0.001) and false positive rate (12% vs 8%, p &lt; 0.001) may be explained by poor adherence to annual screens and an inability to thoroughly ascertain lung cancer diagnosis in all patients due to lost to follow up. In community setting with &lt; 50% adherence to annual screens compared to 95% adherence in NLST, it is unclear if LCS mortality benefit still holds and needs intervention to increase adherence to LCS.
Vulnerability to Pandemic Flu Could Be Greater Today Than a Century Ago
Authors: Rebecca Voelker
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer
Authors: Yao Zhan, Lutao Du, Lishui Wang, Xiumei Jiang, Shujun Zhang, Juan Li, Keqiang Yan, Weili Duan, Yinghui Zhao, Lili Wang, Yunshan Wang, Chuanxin Wang
Journal: Molecular Cancer (2018)

Recently, expression signatures of exosomal long non-coding RNAs (lncRNAs) have been proposed as potential non-invasive biomarkers for cancer detection. In this study, we aimed to develop a urinary exosome (UE)-derived lncRNA panel for diagnosis and recurrence prediction of bladder cancer (BC). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to screen and evaluate the expressions of eight candidate lncRNAs in a training set (208 urine samples) and a validation set (160 urine samples). A panel consisting of three differently expressed lncRNAs (MALAT1, PCAT-1 and SPRY4-IT1) was established for BC diagnosis in the training set, showing an area under the receiver-operating characteristic (ROC) curve (AUC) of 0.854. Subsequently, the performance of the panel was further verified with an AUC of 0.813 in the validation set, which was significantly higher than that of urine cytology (0.619). In addition, Kaplan-Meier analysis suggested that the up-regulation of PCAT-1 and MALAT1 was associated with poor recurrence-free survival (RFS) of non-muscle-invasive BC (NMIBC) (p < 0.001 and p = 0.002, respectively), and multivariate Cox proportional hazards regression analysis revealed that exosomal PCAT-1 overexpression was an independent prognostic factor for the RFS of NMIBC (p = 0.018). Collectively, our findings indicated that UE-derived lncRNAs possessed considerable clinical value in the diagnosis and prognosis of BC.
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
Authors: Elena Lukina, Nora Watman, Marta Dragosky, Heather Lau, Elsa Avila Arreguin, Hanna Rosenbaum, Ari Zimran, Meredith C. Foster, Sebastiaan J. M. Gaemers, M. Judith Peterschmitt
Journal: American Journal of Hematology (2018)

Abstract Eliglustat is a first‐line oral therapy for adults with Gaucher disease type 1 (GD1) and poor, intermediate or extensive CYP2D6‐metabolizer phenotypes (&gt;90% of patients). We report the final results of a Phase 2 trial and extension (NCT00358150) in previously untreated adult GD1 patients who had splenomegaly with thrombocytopenia and/or anemia and received 50 or 100 mg eliglustat tartrate (equivalent to 42 or 84 mg eliglustat) twice daily for 8 years. In total, 19 of 26 patients completed the trial. After 8 years of eliglustat, mean spleen and liver volumes decreased by 69% and 34%, respectively. Mean hemoglobin concentration and platelet count increased by 2.2 g/dL and 113%, respectively. All patients met at least 3 of 4 therapeutic goals established for patients on long‐term enzyme replacement therapy. Mean final values for patients with severe splenomegaly ( n = 6), moderate‐to‐severe anemia ( n = 6), or severe thrombocytopenia ( n = 8) were similar to patients with milder disease at baseline and within long‐term therapeutic goal thresholds. Biomarker median percent changes from baseline were ‐91% for chitotriosidase, ‐87% for CCL18, ‐92% for glucosylsphingosine, and ‐80% for plasma glucosylceramide. Mean lumbar spine T‐score increased by 0.96, moving from the osteopenic to the normal range. Mean quality‐of‐life scores, mostly below normal at baseline, moved into ranges seen in healthy adults. Eliglustat was well‐tolerated; 98% of adverse events were mild or moderate and 94% were considered unrelated to treatment. Clinically meaningful improvements in all parameters continued or were maintained over 8 years, with the largest margins of improvement seen in the most severely affected patients.
Correction to: CART cells are prone to Fas- and DR5-mediated cell death
Authors: Benjamin O. Tschumi, Nina Dumauthioz, Bastien Marti, Lianjun Zhang, Evripidis Lanitis, Melita Irving, Pascal Schneider, Jean-Pierre Mach, George Coukos, Pedro Romero, Alena Donda
Journal: Journal for ImmunoTherapy of Cancer (2018)

AbstractAfter publication of this article [1], it was noticed that 3 authors were missed from the author list.The original article can be found online at 10.1186/s40425-018-0385-z Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Abstract 19510: Regression of Coronary Atherosclerosis With the PCSK9 Inhibitor Evolocumab in Patients With Coronary Artery Disease and Diabetes
Authors: Peta King, Rishi Puri, Wolgang Koenig, Danielle M Brennan, Ransi Somaratne, Helina Kassahun, Scott M Wasserman, Steven E Nissen, Stephen J Nicholls
Journal: Circulation (2017)

Introduction: Diabetes is associated with progressive coronary atherosclerosis. Reduction in LDL-C with high intensity statins promote plaque regression in patients with diabetes and have also been...
Abstract 15978: Variability of Practice Patterns in Device Closure of Atrial Septal Defects and Patent Ductus Arteriosus: An Analysis of Data From the Impact® Registry
Authors: Michael L O’Byrne, Kevin F Kennedy, Jonathan J Rome, Andrew C Glatz
Journal: Circulation (2016)

Introduction: The IMPACT® registry provides the first opportunity to measure practice variation in trans-catheter interventions for congenital heart disease, specifically device closure of atrial s...
Abstract 17167: Targeting Apolipoprotein(a) With a Novel RNAi Delivery Platform as a Prophylactic Treatment to Reduce Risk of Cardiovascular Events in Individuals With Elevated Lipoprotein (a)
Authors: Stacey Melquist, Darren Wakefield, Holly Hamilton, Christine Chapman, Jessica Grondolsky, Casi Schienebeck, Lauren Almeida, Crystal Klas, Collin Hagen, Aaron Almeida, Julia Hegge, Qili Chu, Vladimir Trubetskoy, Edie Doss, Jane Hoover-Plow, David Rozema, David Lewis, Steven Kanner
Journal: Circulation (2016)

Introduction: Mendelian randomization studies and meta-analyses have demonstrated that elevated circulating lipoprotein(a), known as Lp(a), is an independent risk factor for cardiovascular diseases...
Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements
Authors: Rebecca A. Luchtel, Surendra Dasari, Naoki Oishi, Martin Bjerregård Pedersen, Guangzhen Hu, Karen L. Rech, Rhett P. Ketterling, Jagmohan Sidhu, Xueju Wang, Ryohei Katoh, Ahmet Dogan, N. Sertac Kip, Julie M. Cunningham, Zhifu Sun, Saurabh Baheti, Julie C. Porcher, Jonathan W. Said, Liuyan Jiang, Stephen Jacques Hamilton-Dutoit, Michael Boe Møller, Peter Nørgaard, N. Nora Bennani, Wee-Joo Chng, Gaofeng Huang, Brian K. Link, Fabio Facchetti, James R. Cerhan, Francesco d’Amore, Stephen M. Ansell, Andrew L. Feldman
Journal: Blood (2018)
Modulation of E-cadherin and N-cadherin expression levels in human prostate cancer cells based on tumor microenvironment
Authors: Clayton Yates, Haiyen Zhau, Leland Chung
Journal: Cancer Research (2007)

2790  Background: Metastasis is a multi-step processes wherein tumor cells must be able to move from the primary tumor, disseminate throughout the body, and survive to grow in the ectopic locale. During the initial invasion stage, prostate carcinoma cells undergo epithelial mesenchymal-like transition with gain of mesencyhmal marker N-cadherin, and loss of epithelial marker E-cadherin. This switch in cell adhesion expression is thought to enable invasion and dissemination. Recently, several reports have shown that E-cadherin is reexpressed in met static tumors in various cancers including human prostate cancer. This suggests that EMT is not a linear progression, but transient transition conferring survival advantage to the metastasizing cancer cell. Therefore we sought to examine the role of N-cadherin expression in relation to E-cadherin reexpression within bone marrow stromal microenvironment.  Methods: We utilized a human prostate EMT model containing lineage derived ARCaP E cells (express epithelial markers) and ARCaP M cells (express mesencyhmal markers) to delineate EMT associated events during metastasis. ARCaP E & M cells were cocultured with HS-27a human bone marrow cells for various time periods.  Results: Immunocytochemistry of coculture revealed that ARCaP E & M and HS-27a cells express N-cadherin, without E-cadherin expression at day 1 and 2. However, as cocultures persist to day 4 and 6, N-cadherin expression remains in HS-27a cells; however is loss in both ARCaP E & M cells. This changes in cell adhesion expression were not seen in single cultures both cell types. Cell adhesion assay (CAFCA) demonstrated that N-cadherin siRNA pretreatment abrogated attachment of both ARCaP E & M cells to HS-27a cells.  Conclusion: Both ARCaP E & M utilize N-cadherin to adhere to bone marrow stromal cells. However, this expression is transient with E-cadherin predominantly expressed at later time periods. Therefore, we conclude that ARCaP E & M cells exhibit phenotypic variability throughout tumor progression which is modulated by the tumor microenvironment
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials
Authors: Ariadna Tibau, Consolación Molto, Maria Borrell, Joseph C. Del Paggio, Agustí Barnadas, Christopher M. Booth, Eitan Amir
Journal: JAMA Oncology (2018)

This study uses the European Society of Medical Oncology Magnitude of Clinical Benefit Scale to evaluate the clinical benefit of anticancer drugs that gained approval by the US Food and Drug Administration based on single-arm rather than randomized clinical trials.
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Authors: Martin Früh, Daniel C. Betticher, Roger Stupp, Alexandros Xyrafas, Solange Peters, Hans Beat Ris, Rene Olivier Mirimanoff, Adrian F. Ochsenbein, Ralph Schmid, Oscar Matzinger, Rolf A. Stahel, Walter Weder, Matthias Guckenberger, Sacha I. Rothschild, Didier Lardinois, Nicholas Mach, Michael Mark, Oliver Gautschi, Sandra Thierstein, Christine Biaggi Rudolf, Miklos Pless
Journal: Journal of Thoracic Oncology (2018)
Abstract 16193: Crystallized Iron Deposits From Hemorrhagic Myocardial Infarctions Promote Macrophage Polarization Preferentially to a Pro-Inflammatory, M1, Phenotype within Chronic Myocardial Infarcts
Authors: Ivan Cokic, Avinash Kali, Richard Tang, Alice Dohnalkova, Libor Kovarik, Hsin-Jung Yang, Andreas Kumar, Frank S Prato, John C Wood, Joseph Francis, David Underhill, Eduardo Marbán, Rohan Dharmakumar
Journal: Circulation (2016)

Introduction: Reperfusion hemorrhage in acute myocardial infarction (AMI) has been identified as a major contributor to adverse ventricular remodeling. Recent evidence points to hemorrhagic AMI (h-...
Development of a virtual cancer care network for distance oncology treatment.
Authors: Vida Almario Passero, Andrew D. Liman, Hema Rai, Laurie Harrold, John Hotchkiss, Lucy Speerhas, Kaneen Allen, Kristen Veraldi, Joyce Tokarsky, Myra Couch, Jocelyn Tan, Kara Kies, Jenna Shields
Journal: Journal of Clinical Oncology (2018)

270 Background: The VA Pittsburgh Healthcare System (VAPHS) Virtual Cancer Care Network was launched in January 2018 as the next step after we had established an electronic consult service where 555 hematology electronic consults were completed at VAPHS in FY17. The clinical video telehealth (CVT) clinic allows veterans from central Pennsylvania to receive their anticancer therapy at the VA in Altoona, Pennsylvania where the oncology pharmacy, nursing, telehealth, and supportive oncology staff are on site, while the patients continue to follow regularly during treatment via CVT visits with their oncologist located 93 miles away at the VA in Pittsburgh. Methods: A chemotherapy pharmacy and nursing infusion clinic were created at the VA in Altoona. CVT visits started in January 2018. Data including zip code and clinic visit details were examined through descriptive statistics. Results: A total of 89 CVT visits for 27 patients were completed from January 2018 to May 2018. All patient visits were follow-ups while patients were receiving active treatment. 16 patients received intravenous treatments, and 11 received oral anticancer therapy. 100% of the patients were male. Median age was 73 (range 56-89). The most common diagnosis was prostate cancer (26%). The majority of the patients were receiving therapy for palliative intent. 100% of patients chose VA Altoona rather than VAPHS as their treatment clinic location. Five oncology physicians and one oncology clinical nurse specialist completed the clinical video telehealth visits from VAPHS. Total commuting distance averted was 14,828 miles. With an average commuting speed of 60 mph and a travel cost per mile of 0.5 dollars, the total commute time saved for veterans was 247 hours, and the total mileage costs saved was $7414. Appointment compliance was 100%, and there were no missed opportunities. Conclusions: Implementing the Virtual Cancer Care Network has decreased the travel time and costs for veterans who previously would have travelled from central Pennsylvania to VAPHS for their oncology treatment. The integration of CVT technology has improved patient access to oncology care and maintains the patients’ primary relationships with their oncologists.
Who will the Defence and National Rehabilitation Centre rehabilitate?
Authors: J Wilson Carswell
Journal: BMJ (2018)

Macdonald discusses the challenges of rehabilitating soldiers and veterans.1 The Defence and National Rehabilitation Centre was recently opened in the United Kingdom.2 Of the 200 beds for rehabilitation, 80 are reserved for “seriously wounded soldiers.” Presently, it seems destined to fill a non-existent need.

The UK government’s figures show that, from 2014 to 2017 (inclusive), only one member of the armed forces was killed by “hostile action.”3456 With a working ratio of 10 injured for every fatality, this leaves very few physically …
Antidepressant adviser to government quits after conflict of interest row
Authors: Gareth Iacobucci
Journal: BMJ (2018)

An adviser to the government on antidepressant use has quit in the wake of a row over conflicts of interest.

David Baldwin resigned from Public Health England’s expert panel on prescribed medicines after he was subjected to a string of insults online, including being called “worse than Hitler” and a “pharma-whore,” the Times has reported.1

Baldwin was the Royal College of Psychiatrists’ representative on the panel, which was set up to review the potential effects of withdrawing from prescribed drugs. But he was criticised after he co-wrote a letter to the Times in February that downplayed the side effects of coming off antidepressants.2 The letter, coauthored with Wendy Burn, president of the Royal College of Psychiatrists, read, “In the vast …
Use of pregabalin for preemptive analgesia in an enhanced recovery after surgery program.
Authors: Katherine Cain, Nhi Hoang, Maria Iniesta, Brandelyn Pitcher, Camila Corzo, Larissa Meyer, Javier Lasala, Pedro T Ramirez
Journal: Journal of Clinical Oncology (2018)

265 Background: A key component of any Enhanced Recovery After Surgery (ERAS) program is standardized multimodal analgesia to minimize opioid use. Our program utilizes acetaminophen, nonsteroidal anti-inflammatory agents and gabapentanoids perioperatively. The primary aim of our study was to evaluate pregabalin use after surgery and impact on total morphine equivalent daily dose (MEDD). Methods: Data was collected retrospectively on consecutive ERAS patients who underwent open gynecologic surgery from 3/4/2016 through 2/22/2018. We excluded any patient identified as a chronic opioid user. Standard preoperative medications included 300 mg tramadol ER, 75 mg pregabalin, and 400 mg celecoxib per institutional guidelines. Standard postoperative pain regimen included scheduled oral acetaminophen, ibuprofen and pregabalin unless contraindicated with rescue oral oxycodone and IV hydromorphone as needed. Pregabalin was ordered 75 mg twice daily for 4 doses. Recommended exceptions to pregabalin included hypersensitivity or age greater than 65 years. Median and range were calculated to summarize continuous variables. Spearman’s rank was used to test the correlation between post-operative pregabalin dose and MEDD. Results: A total of 533 patients were included for analysis. Twelve patients were excluded for chronic opioid use. 38% of patients received all four post-operative pregabalin doses (207/533). 32.8% of patients received no pregabalin (175/533). The fourth dose was the most common missed dose (274/533, 51.4%). The top reasons dose 4 was missed included not being ordered (58.8%) and patient already discharged (12.4%). There were 202 patients older than 65 years, the majority of these patients received no post-operative pregabalin (123/202, 60.9%). There was no difference in the amount of MEDD between those who received all pregabalin doses compared to those who received none (90.75 mg [4-663.5 mg] vs 82.5 mg [4-634.5 mg]; p = 0.269). Conclusions: Pregabalin for preemptive analgesia in an ERAS program does not decrease MEDD.
Abstract 15035: Liraglutide Reduces Major Cardiovascular Events in Patients With Chronic Kidney Disease: Results From the Leader Trial
Authors: Neil R Poulter, Johannes Mann, Vivian Fonseca, Ofri Mosenzon, Itamar Raz, Helle Frimer-Larsen, Bernt Johan von Scholten, Thomas Idorn
Journal: Circulation (2017)

Introduction: People with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at high risk of cardiovascular (CV) events. We analyzed the effect of liraglutide vs placebo (PBO) on CV outcome...
Abstract 17442: Retinoic Acid Protocol Combined With Glucose Starvation and Matrigel Plating Enhances Commitment of Human IPSC-derived Cardiomyocytes Into Atrial-like Phenotype
Authors: Mariana Argenziano, Eleonora Savio Galimberti, Dawood Darbar
Journal: Circulation (2016)

Introduction: Current cardiomyocytes (CMs) derived from human induced pluripotent stem cells (hIPSC) mainly recapitulate immature ventricular-like phenotypes. However, this approach has not yet bee...
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Authors: Wei Shen Tan, Anesh Panchal, Laura Buckley, Adam J. Devall, Laurence S. Loubière, Ann M. Pope, Mark R. Feneley, Jo Cresswell, Rami Issa, Hugh Mostafid, Sanjeev Madaan, Rupesh Bhatt, John McGrath, Vijay Sangar, T.R. Leyshon Griffiths, Toby Page, Dominic Hodgson, Shibendra N. Datta, Lucinda J. Billingham, John D. Kelly
Journal: European Urology (2018)